 |
Indication & Dosage |
| |
| |
| Oral |
| MONOTHERAPY OR ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES WITH OR WITHO SECONDARY GENERALISED TONIC-CLONIC SEIZURES |
| Adult:
Initially, 600 mg daily in 2 divided doses; increase at a max increments of 600 mg daily at wkly intervals depending on response. Maintenance: 600-1,200 mg daily. Adjunctive therapy/refractory patients switched from other anticonvulsants: Up to 2,400 mg daily. |
| |
| Oral |
| MONOTHERAPY OR ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES WITH OR WITHO SECONDARY GENERALISED TONIC-CLONIC SEIZURES |
| Child:
>6 yr: 8-10 mg/kg daily in 2 divided doses; increase as necessary to max increments of 10 mg/kg daily at about wkly intervals to a max of 46 mg/kg daily. Maintenance in adjunctive therapy: 30 mg/kg daily. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Cross-sensitivity to carbamazepine may occur. Do not discontinue abruptly. Renal and hepatic impairment. Patients at risk of hyponatraemia. May impair ability to drive or operate machinery. Pregnancy. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Dizziness, somnolence, headache, ataxia, fatigue, vertigo, nervousness, amnaesia, abnormal thinking, insomnia, speech disorder, agitation, confusion; vomiting, nausea, abdominal pain, diarrhoea, dyspepsia, constipation, gastritis, wt gain; abnormal gait, tremor, weakness, back pain, abnormal coordination, dysmetria, sprains/strains, muscle weakness; diplopia, nystagmus, abnormal vision and accommodation; hypotension, leg oedema; rash, acne; hyponatraemia; rhinitis, chest infection, epistaxis, sinusitis. |
| |
|
| Adverse Drug Reactions |
Stevens-Johnson syndrome, toxic epidermal necrolysis. Anaphylaxis and angioedema. |
| |
|
| Interactions |
Reduced serum levels with carbamazepine, phenobarbitone, phenytoin, valproic acid. May reduce levels/effects of CYP3A4 substrates (e.g. benzodiazepines, calcium channel blockers, clarithromycin, ciclosporin, erythromycin, estrogens, mirtazapine, nateglinide, nefazodone, nevirapine, protease inhibitors, tacrolimus, venlafaxine). May reduce efficacy of oral contraceptives. May reduce levels/effects of maraviroc. May increase levels of phenobarbitone, phenytoin.
|
| |
|
|
|
